

Humanigen CEO Cameron Durrant to Chair Vanguard Forum for Life Sciences Leaders

NEW YORK — The Vanguard Group for Leadership announced today that Dr. Cameron Durrant will chair the virtual Vanguard Forum for Life Sciences Leaders on Oct 21 and 22.

Dr. Durrant is Chairman and CEO of Humanigen, the California-based life sciences company whose experimental COVID-19 treatment, lenzilumab, has been shown to reduce the risk of mechanical ventilation and death for severe COVID-19 patients by 80 percent.¹

Dr. Durrant has been on the advisory board of Vanguard since its creation in 2014 by founder and principal Ken Banta, and has also been a regular Vanguard session leader at Vanguard Forums.

“Vanguard is an exceptional resource for top leaders,” said Dr. Durrant, “I am honored to be chairing the Vanguard Life Sciences Forum.”

The Forum for Life Sciences Leaders is an invitation-only event for current and future C-suite leaders in earlier-stage life sciences companies. This year, it will focus on how top leaders can drive the recovery of their organizations from the pandemic impacts, and catalyze high performance for the long term.

Forums are produced by the Vanguard Group’s membership organization, the Vanguard Network, which supports C-suite leaders and other top executives in honing their leadership capabilities.

In addition to its work with healthcare and life sciences leaders, the Vanguard Network is active with General Counsels across all sectors, non-profit leaders, and young science leaders — the latter in collaboration with The Aspen Institute.

Vanguard’s roster of more than 100 faculty and session leaders include David Pyott (Royal Dutch Philips), Ashley McEvoy (J&J), and Tom Sabatino (past GC of Aetna, Hertz and Walgreens).

Ken Banta, the Vanguard Group’s founder and principal, is a top management advisor who works with CEOs and senior executives on leadership, organizational transformation and corporate positioning. Ken has helped to lead eleven successful global transformations and turn-arounds, and has advised on many more. Ken writes regularly for HBR and is a Contributing Author of “HBR’s 10 Must Reads for CEOs.”

For more information about the Vanguard Group for Leadership, visit
<https://www.thevanguardgroupforleadership.com>.

Contact

Irene Silber

Associate Principal

The Vanguard Group for Leadership

irene@vanguardgroup.nyc

(612) 516-6068

References

1. Temesgen, Z., M. Assi, P. Vergidis, S. A. Rizza, P. R. Bauer, B. W. Pickering, R. R. Razonable, C. R. Libertin, C. D. Burger, R. Orenstein, H. E. Vargas, B. R. Varatharaj Palraj, A. S. Dababneh, G. Chappell, D. Chappell, O. Ahmed, R. Sakemura, C. Durrant, S. S. Kenderian and A. Badley (2020). "First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia." medRxiv.